An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

CNBC host Jim Cramer continues to pound the table on Eli Lilly’s (LLY) stock. The host of the TV show “Mad Money” continues to be a cheerleader for LLY stock, saying repeatedly that the pharmaceutical ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

A weekend focused on women’s health and women’s basketball, all in Eli Lilly’s home state of Indiana? Consider that a layup ...

The Eli Lilly and Company Foundation awarded a multi-year grant of up to $5.5 million to the Indianapolis Public Schools (IPS ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

IPS middle and high schoolers will soon get to have more hands-on expereince in STEM curriculums and fields as part of a $5.5M Lilly grant.

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...